Press Releases

- Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of antibodies against SARS-CoV-2 - Ortho's new VITROS ®  Anti-SARS-CoV-2 IgG Quantitative Antibody
May 21, 2021
RARITAN, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to present in two upcoming investor conferences: UBS Virtual Global
May 20, 2021
First Quarter Revenue Growth Exceeds Company’s Expectations at 24.2%, Supporting Increase in 2021 Guidance RARITAN, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today
May 05, 2021
Displaying 1 - 10 of 102